Optimal glucocorticoid therapy in lupus nephritis
Nephrology Dialysis Transplantation · 30.06.2025 · 40 (7) · 1284-1293
DOI: 10.1093/ndt/gfae294 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.12.2024. Verfasst von Gabriel Figueroa-Parra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Service, Department of Internal Medicine, University Hospital "Dr José Eleuterio González", Universidad Autónoma de Nuevo León, Monterre…. Hauptthemen laut MEDLINE: Glucocorticoids, Lupus Nephritis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: CDC HHS, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients. LN significantly increases the risk of mortality and progression to end-stage kidney disease. Glucocorticoids have been central to LN treatment for decades due to their anti-inflammatory properties, but optimal dosing strategies remain uncertain. The review discusses the historical evolution of glucocorticoid use, highlighting the shift from high-dose regimens to combined approaches with immunosuppressants and lower glucocorticoid doses to minimize adverse effects. Mechanistically, glucocorticoids exert effects through genomic and non-genomic pathways, modulating immune responses and metabolism. Long-term use is associated with risks such as infection, osteoporosis, hyperglycemia and cardiovascular disease. The review examines different dosing strategies, including intravenous pulse therapy and oral regimens, and presents evidence of their efficacy and safety. It also explores alternative approaches, such as low-dose and glucocorticoid-free regimens, which show promise but require further study. The review concludes by emphasizing the need for future research to optimize glucocorticoid regimens, refine tapering protocols and identify safer therapeutic combinations, as glucocorticoids remain a cornerstone in LN management despite their challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Service, Department of Internal Medicine, University Hospital "Dr José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México.
- Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Gabriel Figueroa-Parra, Erika Navarro-Mendoza
Förderung
- CDC HHS
- Centers for Disease Control and Prevention
Zitieren
APA
Figueroa-Parra, G., Bautista-Vargas, M., Navarro-Mendoza, E., & Duarte-García, A. (2025). Optimal glucocorticoid therapy in lupus nephritis. Nephrology Dialysis Transplantation, 40(7), 1284-1293. https://doi.org/10.1093/ndt/gfae294
Vancouver
Figueroa-Parra G, Bautista-Vargas M, Navarro-Mendoza E, Duarte-García A. Optimal glucocorticoid therapy in lupus nephritis. Nephrology Dialysis Transplantation. 2025;40(7):1284-1293. doi:10.1093/ndt/gfae294
BibTeX
@article{FigueroaParra2025,
author = {Figueroa-Parra, Gabriel and Bautista-Vargas, Mario and Navarro-Mendoza, Erika and Duarte-García, Alí},
title = {Optimal glucocorticoid therapy in lupus nephritis},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {7},
pages = {1284--1293},
doi = {10.1093/ndt/gfae294}
}
EUVIMED